AveXis to Report Second Quarter 2016 Financial and Operating Results and Interim Data from Ongoing Phase 1 Trial of AVXS-101 ...
August 02 2016 - 8:00AM
AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company
developing treatments for patients suffering from rare and
life-threatening neurological genetic diseases, will announce
financial and operating results for second quarter ended June 30,
2016 on Thursday, August 11, 2016 after the close of U.S.-based
financial markets. AveXis management will host a conference call
and live webcast to provide a business update, as well as interim
data from the ongoing Phase 1 trial of AVXS-101 in spinal muscular
atrophy (SMA) Type 1, at 4:30 p.m. Eastern Daylight Time.
Analysts and investors can participate in the conference call by
dialing (877) 508-0547 for domestic callers and (281) 973-6085 for
international callers, using the conference ID 57726673. The
webcast can be accessed live on the Events and Presentations page
in the Investors and Media section of the AveXis website,
www.AveXis.com. The webcast will be archived on the company’s
website until its next earnings call, and will be available for
telephonic replay for 14 days following the call by dialing (855)
859-2056 (Domestic) or (404) 537-3406 (International), conference
ID 57726673.
About SMASMA is a severe neuromuscular disease
characterized by the loss of motor neurons leading to progressive
muscle weakness and paralysis. SMA is caused by a genetic defect in
the SMN1 gene that codes SMN, a protein necessary for survival of
motor neurons. The incidence of SMA is approximately one in 10,000
live births.
The most severe form of SMA is Type 1, a lethal genetic disorder
characterized by motor neuron loss and associated muscle
deterioration, which results in mortality or the need for permanent
ventilation support before the age of two for greater than 90
percent of patients. SMA Type 1 is the leading genetic cause of
infant mortality.
About AVXS-101AVXS-101 is a proprietary gene
therapy candidate of a one-time treatment for SMA Type 1 and is the
only clinical-stage gene therapy in development for SMA. AVXS-101
is designed to address the monogenetic root cause of SMA and
prevent further muscle degeneration by addressing the defective
and/or loss of the primary SMN gene. AVXS-101 also targets motor
neurons providing rapid onset of effect, and crosses the blood
brain barrier allowing an IV dosing route and effective targeting
of both central and systemic features.
About AveXis, Inc.AveXis is a clinical-stage
gene therapy company developing treatments for patients suffering
from rare and life-threatening neurological genetic diseases. The
company’s initial proprietary gene therapy candidate, AVXS-101, is
in an ongoing Phase 1 clinical trial for the treatment of SMA Type
1. For additional information, please visit www.avexis.com.
Media Inquiries:
Lauren Barbiero
W2O Group
646-564-2156
lbarbiero@w2ogroup.com
Investor Inquiries:
Jim Goff
AveXis, Inc.
650-862-4134
jgoff@avexis.com
AVEXIS, INC. (NASDAQ:AVXS)
Historical Stock Chart
From Jun 2024 to Jul 2024
AVEXIS, INC. (NASDAQ:AVXS)
Historical Stock Chart
From Jul 2023 to Jul 2024